Please login to the form below

NPS

This page shows the latest NPS news and features for those working in and with pharma, biotech and healthcare.

Shire finally bags EU approval for rare disease drug Natpar

Natpar was one of the primary reasons Shire forked out $5.2bn to buy NPS Pharma in 2015 just before the FDA gave its go-ahead for the new therapy, which

Latest news

Sweet emotion

1100%; improving NPS scores.
Finalists revealed for Communiqué Awards 2016

Think Again. Think NP-C - an international campaign to increase NP-C recognition among clinicians and reduce time to diagnosis.
Shire deal with Baxalta predicted this week

HAE) therapy DX-2930 - and a $5.2bn purchase of NPS Pharma which gave it control of Natpara (recombinant parathyroid hormone) for hypoparathyroidism.
Shire makes shock $30bn bid for Baxalta

This came several months after the firm agreed to buy NPS for $5.2bn, gaining access to its lead product Natpara (recombinant parathyroid hormone) to treat low blood calcium levels in
Shire rumoured to be pursuing Actelion

Last month, Alexion unveiled an $8.4bn agreement to buy rare disease specialist Synageva, while Shire itself agreed to buy NPS for $5.2bn earlier this year.

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Digital mania - a question of value

So bad in fact, that the best Net Promoter Score (NPS) is a whopping -40% (minus!).
A rare talent

Before that the firm had a busy 2015, buying US rare disease-focused biotech NPS Pharma for $5.2bn and rare disease and gastrointestinal company Meritage Pharma for at least $70m
Deal Watch table for January 2015

NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome.
Pharma deals during January 2015

Top of the table was the all cash acquisition of NPS Pharmaceuticals by Shire for a total of $5.2bn just one year on from its acquisition of ViroPharma.
Pharma deals during June 2014

Hot gossip. Rumours were posted by the Financial Times that Shire was about to make a $5bn bid for NPS Pharmaceuticals. ... So strong were the rumours that this led to NPS issuing an official denial.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

Prevail Therapeutics adds to its board of directors

From 2008-2015 Nader was president and chief executive officer of NPS Pharma, until Shire acquired the company for $5.2bn. ... Before his time at NPS, Nader was a venture partner at Care Capital and he also previously served on the North America
CRISPR Therapeutics appoints Dr Tony Coles

He has also previously held executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb and Merck &Co.
Patrick Fabbio named CFO at electroCore

Patrick Fabbio named CFO at electroCore. He joins from NPS Pharmaceuticals where he was VP finance. ... Fabbio has over 20 years of financial leadership experience in public and private life science and pharmaceutical companies, most recently as VP

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

Packer Forbes News December 2015

Think NP-C’ campaign, the Packer Forbes team in collaboration with the INPDA and Actelion were delighted to be shortlisted as a finalist for the prestigious Pharmaceutical Market Excellence Awards (PMEA) ... Think NP-C’ campaign, which works towards
Packer Forbes News March 2016

The international Think Again. Think NP-C campaign, which encourages clinicians to recognise and link the symptoms of the rare and devastating disease, Niemann-Pick Type C (NP-C), has been ... Think NP-C has been acknowledged for its significant impact
Four Health Communications

We are particularly proud to have launched European HIV-Hepatitis Testing Week and Think Again, Think NP-C, which have been independently recognised with industry awards and, more importantly, improved the